The implications of propensity score variable selection strategies in pharmacoepidemiology: An empirical illustration

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 6, 2011, Pages 551-559

  Patrick, Amanda R ^a   Schneeweiss, Sebastian ^a   Brookhart, M Alan ^b   Glynn, Robert J ^a,c   Rothman, Kenneth J ^d   Avorn, Jerry ^a   Stürmer, Til ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b IL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d RTI HEALTH SOLUTIONS   (United States)

Author keywords

Confounding factors; Epidemiologic methods; Hydroxymethylglutaryl CoA reductase inhibitors; Pharmacoepidemiology

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; FEMALE; GLAUCOMA; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; AGED, 80 AND OVER; BIAS (EPIDEMIOLOGY); CONFOUNDING FACTORS (EPIDEMIOLOGY); EPIDEMIOLOGIC METHODS; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA; HIP FRACTURES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PHARMACOEPIDEMIOLOGY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79959558713     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2098     Document Type: Article

References (32)

1. Rosenbaum P, Rubin D.The central role of the propensity score in observational studies for causal effects.Biometrika 1983;70:41-55.
2. Shah BR, Laupacis A, Hux JE, Austin PC.Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review.J Clin Epidemiol 2005;58(6):550-559.
3. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S.A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods.J Clin Epidemiol 2006;59:437-447.
4. D'Agostino RB Jr.Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.Stat Med 1998;17(19):2265-2281.
5. Stürmer T, Schneeweiss S, Brookhart MA, Rothman KJ, Avorn J, Glynn RJ.Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly.Am J Epidemiol 2005;161(9):891-898.
6. Maldonado G, Greenland S.Simulation study of confounder-selection strategies.Am J Epidemiol 1993;138(11):923-936.
7. Drake C.Effects of misspecification of the propensity score on estimators of treatment effect.Biometrics 1993;48:1231-1236.
8. Rubin DR, Thomas N.Matching using estimated propensity score: relating theory to practice.Biometrics 1996;52:249-264.
9. Brookhart MA, Schneeweiss S, Rothman KJ, Avorn J, Stürmer T.Variable selection in propensity score models.Am J Epidemiol 2006;163(12):1149-1156.
10. Bhattacharya J, Vogt WB. Do instrumental variables belong in propensity scores?Working Paper 343, National Bureau of Economic Research, 2007.
11. Weitzen S, Lapane KL, Toledano AY, Hume AL, Mor V.Principles for modeling propensity scores in medical research: a systematic literature review.Pharmacoepidemiol Drug Saf 2004;13(12):841-853.
12. Glynn RJ, Knight EL, Levin R, Avorn J.Paradoxical relations of drug treatment with mortality in older persons.Epidemiology 2001;12(6):682-689.
13. Schneeweiss S, Patrick AR, Stürmer T, et al.Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results.Med Care 2007;45 (10 Supl 2):S131-S142.
14. Glynn RJ, Schneeweiss S, Wang PS, Levin R, Avorn J.Selective prescribing led to overestimation of the benefits of lipid-lowering drugs.J Clin Epidemiol 2006;59(8):819-828.
15. Ray WA.Evaluating medication effects outside of clinical trials: new-user designs.Am J Epidemiol 2003;158(9):915-920.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR.A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.J Chron Dis 1987;40:373-383.
17. Baron JA, Lu-Yao G, Barrett J, McLerran D, Fisher ES.Internal validation of medicare claims data.Epidemiology 1994;5(5):541-544.
18. Copeland KT, Checkoway H, McMichael AJ, Holbrock RH.Bias due to misclassification in the estimation of relative risk.Am J Epidemiol 1977;105:488-495.
19. Roberts CGP, Guallar E, Rodriguez A.Efficacy and safety of statin monotherapy in older adults: a meta-analysis.J Gerontol A Biol Sci Med Sci 2007;62:879-887.
20. Toh S, Hernández-Díaz S.Statins and fracture risk: a systematic review.Pharmacoepidemiol Drug Saf 2007;16(6):627-640.
21. Strom BL. (ed).Pharmacoepidemiology (4th edn).John Wiley & Sons Ltd.: Hoboken, NJ, 2005.
22. Weitzen S, Lapane KL, Toledano AY, Hume AL, Mor V.Weaknesses of goodness-of-fit tests for evaluating propensity score models: the case of the omitted confounder.Pharmacoepidemiol Drug Saf 2005;14(4):227-238.
23. Robins JM, Mark SD, Newey WK.Estimating exposure effects by modelling the expectation of exposure conditional on confounders.Biometrics 1992;48(2):479-495.
24. Joffe MM, Rosenbaum PR.Invited commentary: propensity scores.Am J Epidemiol 1999;150(4):327-333.
25. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S.Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable.Epidemiology 2006; (3):268-275.
26. de Vries F, de Vries C, Cooper C, Leufkens B, van Staa TP.Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database.Int J Epidemiol 2006;35(5):1301-1308.
27. Chan KA, Andrade SE, Boles M, et al.Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women.Lancet 2000;355(9222):2185-2188.
28. LaCroix AZ, Cauley JA, Pettinger M, et al.Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study.Ann Intern Med 2003;139(2):97-104.
29. Rubin DB.The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials.Stat Med 2007;26(1):20-36.
30. Hansen BB.The prognostic analogue of the propensity score.Biometrika 2008;95(2):481-488.
31. Arbogast PG, Ray WA.Use of disease risk scores in pharmacoepidemiologic studies.Stat Methods Med Res 2009;18(1):67-80.
32. Brookhart MA, Stürmer T, Glynn RJ, Rassen J, Schneeweiss S.Confounding control in healthcare database research: challenges and potential approaches.Med Care 2010;48 (6 Suppl):S114-S120.